TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11883725
Drug: Post-treatment sense
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment sense of control/internal attribution
Study: 1971516
Drug: Terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 120 mg once daily
Study: 31233135
Drug: Home-based telerehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based telerehabilitation (TR) system, 36 sessions of arm motor therapy plus stroke education, 70 minutes each session.
Study: 31233135
Drug: In-clinic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-clinic therapy (IC), 36 sessions of arm motor therapy plus stroke education, 70 minutes each session.
Study: 3906162
Drug: Travasorb‐Hepatic (BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travasorb‐Hepatic (BCAA rich supplement)
Study: 3906162
Drug: Ensure (casein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensure (casein based supplement)
Study: 31591739
Drug: Low-dose decitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose decitabine
Study: 25877498
Drug: Brodalumab 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 70 mg
Study: 15679722
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate 400 microg nasal spray
Study: 15679722
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate 200 microg nasal spray
Study: 14532926
Drug: RBC-C (ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC-C (ranitidine bismuth citrate 400 mg plus clarithromycin 500 mg)
Study: 14532926
Drug: OCA (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA (omeprazole 20 mg, clarithromycin 500 mg and amoxicillin 1000 mg)
Study: 6724467
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline therapy (193.2 mg Theophyllinmonohydrat)
Study: 6724467
Drug: Systemic application
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic application (46.8 mg Aethylendiamin as Euphyllin)
Study: 29863694
Drug: Mexidol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol (200 mg intravenously for 10 days, then 2 tablets 0.125 mg twice a day for 8 weeks)
Study: 10726785
Drug: Fortified gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified gentamicin ointment (1.5%)
Study: 10726785
Drug: Both ointment
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both ointment and drops
Study: 31362729
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of flipped classroom with problem-based learning (CG)
Study: 30107042
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate (1200 mg elementary calcium/daily)
Study: 30107042
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1200 mg elementary calcium/daily)
Study: 16027399
Drug: Intravenous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous epoetin alfa administration
Study: 16027399
Drug: Subcutaneous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epoetin alfa administration
Study: 9880451
Drug: rhu GM‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhu GM‐CSF (8 microg/kg/d), administered intravenously over 2 hours daily for 7 days and every other day for 21 days
Study: 7720346
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (n = 25)
Study: 23077973
Drug: Bedtime therapy
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime therapy with at least one hypertension medication
Study: 24708031
Drug: Indacaterol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol (150 μg once daily)
Study: 18825368
Drug: AVP response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AVP response in patients with chronic angiotensin-converting enzyme inhibitor therapy
Study: 17052901
Drug: Albuterol (7.5mg/h)
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (7.5mg/h)
Study: 15288384
Drug: Trexan without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trexan without amino-acid therapy
Study: 11594942
Drug: Antioxidants plus
Normalized name: Homosalate 100 mg in 1 mL / Octisalate 50 mg in 1 mL / Octocrylene 40 mg in 1 mL TOPICAL CREAM [LOreal Paris Age Perfect Radiant Foundation Broad Spectrum SPF 50 Sunscreen with Antioxidants plus Concentrated Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants plus zinc (vitamin C 500 mg, vitamin E 400 IU, beta carotene 15 mg, zinc 80 mg)
Study: 11594942
Drug: Zinc alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc alone (80 mg)
Study: 27716324
Drug: Sarilumab 150
Normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 150 mg every 2 weeks (q2w)
Study: 23299383
Drug: Daily doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily doses of 400 IU of vitamin E and 200 µg of selenium
Study: 23297680
Drug: RTS,S/AS02(D) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS02(D) vaccine
Study: 10969114
Drug: Click test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Click test for surfactant therapy
Study: 10969114
Drug: Usual clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual clinical and chest radiograph criteria for surfactant therapy
Study: 6379345
Drug: Diclofensine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofensine (2 X 25 mg/day for 30 days)
Study: 20174642
Drug: Community-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based treatment by Health Extension Workers (HEWs)
Study: 20174642
Drug: Community-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based treatment by HEWs
Study: 20174642
Drug: Involving HEWs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involving HEWs in TB treatment
Study: 14563144
Drug: 700‐cGy external‐beam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700‐cGy external‐beam irradiation to the operative site 24 hours prior to reexploration and decompressive treatment
Study: 12734710
Drug: Kennedy ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kennedy ligament augmentation device (LAD)
Study: 8896099
Drug: No augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No augmentation (non-augmented knee group)
Study: 2050831
Drug: HCTZ 50
Normalized name: HCTZ 50 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 50 mg daily
Study: 6084123
Drug: guanabenz 16
Normalized name: guanabenz 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: guanabenz 16 mg/hydrochlorothiazide 25 mg (combination tablet)
Study: 31722312
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection with E0302 50 mg, twice a week for 16 weeks
Study: 23480216
Drug: PEG 3350+E
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 3350+E (26 g split dose daily)
Study: 23480216
Drug: Prucalopride (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride (1-2 mg daily)
Study: 15107913
Drug: EDTA-T gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA-T gel (pH 7.0) at concentrations of 5%, 10%, 15%, 20%, and 24% (n = 100)
Study: 15107913
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline solution, n = 20)
Study: 11707790
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (EF) - 17 mL of 2% lidocaine plus 100 microg fentanyl
Study: 24139497
Drug: Leukotriene Receptor
Normalized name: Leukotriene receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene Receptor Antagonist and Inhaled Corticosteroid
Study: 23497032
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment at 6 standard acupuncture points (ST36, ST35, ST34, SP9, Ex‐LE04, and SP10) 3 times per week for 4 weeks (total of 12 sessions)
Study: 16546850
Drug: TMD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMD treatment
Study: 29370120
Drug: VMP (dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMP (dietary multivitamin, multimineral and phytonutrient supplement)
Study: 24874533
Drug: Transforaminal corticosteroid
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal corticosteroid injections
Study: 2933253
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ketanserin
Study: 30443883
Drug: Ultrasound (US)
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound (US) treatment and Transcutaneous Nerve Stimulation (TENS) plus exercise
Study: 26063002
Drug: Quaternary ammonium
Normalized name: Quaternary ammonium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quaternary ammonium compound-based sanitizing wipe used at least once per day
Study: 3845028
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg Sulprostone gel
Study: 3845028
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg Sulprostone gel
Study: 26523885
Drug: 7-module internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-module internet-delivered cognitive behavioral therapy (iCBT) program
Study: 23348981
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (3000 mg per day)
Study: 12862363
Drug: Cyclical etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical etidronate (200 mg daily for 2 weeks every 3 months) for 18 months
Study: 12862363
Drug: Cyclical etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical etidronate for 12 months followed by alendronate (5 mg daily) for 6 months
Study: 10547251
Drug: Amoxicillin/clavulanate (Augmentin)
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (Augmentin) 45 mg/kg/d in 2 divided doses for 10 days
Study: 10547251
Drug: Azithromycin (Zithromax),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (Zithromax), 10 mg/kg on the first day, followed by 5 mg/kg daily for 4 days
Study: 1885826
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% lidocaine jelly
Study: 6889218
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (propranolol + nifedipine)
Study: 24285582
Drug: Extended-release (ER)
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release (ER) niacin
Study: 24408212
Drug: Varenicline (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (active medication)
Study: 20028707
Drug: Fingolimod 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 1.25 mg, once daily
Study: 20028707
Drug: Fingolimod 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 5.0 mg, once daily (switched to 1.25 mg during months 15-24)
Study: 16871270
Drug: Open-label sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label sildenafil (50 mg adjustable to 100 mg)
Study: 12015689
Drug: Cefazolin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (2 g iv) plus probenecid (1 g by mouth)
Study: 12015689
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g iv) plus oral placebo
Study: 10506666
Drug: Corticotropin-releasing-hormone (CRH)
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing-hormone (CRH) 100 microg (i.v.)
Study: 10506666
Drug: Corticotropin-releasing-hormone (CRH)
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing-hormone (CRH) with pre-treatment with dexamethasone
Study: 15799918
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of platelet hyperreactivity, marginal graft flow, and endothelial disease
Study: 10924781
Drug: 6 EU
Normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 EU vaccine
Study: 10924781
Drug: 12 EU
Normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 EU vaccine
Study: 10924781
Drug: Reference vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference vaccine
Study: 8931413
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 750 mg t.i.d. and metronidazole 500 mg t.i.d. for 14 days (group III)
Study: 8931413
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. plus clarithromycin 500 mg t.i.d. for 14 days (group IV)
Study: 3597990
Drug: d-sotalol (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-sotalol (1, 1.5 or 2 mg/kg body weight)
Study: 22858800
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NC)
Study: 29132404
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg FP-1201-lyo administered intravenously once daily for 6 days
Study: 29132404
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously once daily for 6 days
Study: 29132404
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg FP-1201-lyo
Study: 26314817
Drug: Fp MDPI
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fp MDPI 800 μg (400 μg/inhalation × 2 inhalations)
Study: 26314817
Drug: Fp DPI
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fp DPI 1000 μg (250 μg/inhalation × 4 inhalations)
Study: 26314817
Drug: Fp MDI
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fp MDI 880 μg (220 μg/inhalation × 4 inhalations)
Study: 8809957
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of antibody prior to transfusions
Study: 8809957
Drug: HLA-antibodies reacting
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA-antibodies reacting with over 95% of unselected lymphocytes
Study: 22986318
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) lidocaine
Study: 20520820
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) immunization with inactivated influenza vaccine (TETAGRIP)
Study: 20520820
Drug: Transcutaneous application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous application of inactivated influenza vaccine (TETAGRIP)
Study: 12455077
Drug: Verapamil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (1 mg over 2 min) administered via an infusion catheter distal to the angioplasty site.
Study: 8969027
Drug: Papaverine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine administered intraluminally, retrograde in the internal mammary artery
Study: 8969027
Drug: Papaverine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine administered topically
Study: 3885884
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg every 6 hours for one week)
Study: 26949378
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein hydrolysate-carbohydrate beverage (PRO-CHO, 14 g protein/h and 69 g CHO/h)
Study: 25557316
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (2000 IU cholecalciferol daily)
Study: 12973482
Drug: Gentamicin at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin at a dose of 4 mg/kg every 24 hours (protocol group)
Study: 12973482
Drug: Gentamicin at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin at a dose of 2.5 mg/kg every 12 hours (control group)
Study: 8717567
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 0.5 mg of Syntometrine
Study: 1828508
Drug: Couple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couple therapy (T) group, N = 33
Study: 21389626
Drug: Casein hydrolysate
Normalized name: casein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein hydrolysate tablets (5 times more than the effective amount)
Study: 19631773
Drug: Low-intensity pulsed
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity pulsed ultrasound treatment
Study: 17920202
Drug: Topical antimicrobials
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimicrobials
Study: 14689459
Drug: Multisensory intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multisensory intervention (auditory, tactile, visual stimulation) for 15 min, twice a day, 5 days a week, for 4 weeks
Study: 3240634
Drug: Nine-week program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine-week program of submaximal aerobic exercise three times weekly
Study: 31621251
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (A)
Study: 21512498
Drug: Neyromidin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neyromidin (15 mg intramuscularly 1 time a day for 10 days)
Study: 21512498
Drug: Cerebrolysin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (10 ml intravenously 1 time a day for 10 days)
Study: 12870569
Drug: Quetiapine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (600 mg/day)
Study: 16162678
Drug: 13C‐UBT 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13C‐UBT 25 mg
Study: 16162678
Drug: 13C‐UBT 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13C‐UBT 15 mg
Study: 16162678
Drug: 13C‐UBT 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13C‐UBT 10 mg
Study: 16162678
Drug: 13C‐UBT 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13C‐UBT 15 mg (post-treatment)
Study: 12783624
Drug: Solution-focused follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-focused follow-up
Study: 9355903
Drug: Bidisomide 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bidisomide 400 mg BID
Study: 9355903
Drug: Bidisomide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bidisomide 600 mg BID
Study: 9355903
Drug: Bidisomide 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bidisomide 200 mg BID
Study: 8473088
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (cefoxitin)
Study: 3318897
Drug: Felodipine 2.5
Normalized name: felodipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 2.5 mg twice daily
Study: 2894980
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg twice daily
Study: 2894980
Drug: Felodipine 10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 10 mg twice daily
Study: 2894980
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo twice daily
Study: 29747611
Drug: Simulated surgical
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated surgical crown lengthening with 1.0 mm buccal ferrule (Group CL/F1)
Study: 29747611
Drug: Simulated surgical
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated surgical crown lengthening with 2.0 mm buccal ferrule (Group CL/F2)
Study: 20467146
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy device with defibrillator (CRT-D)
Study: 8694041
Drug: Inhaled beclomethasone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone, beta 2‐adrenergic receptor agonist, and an oral corticosteroid taper
Study: 8694041
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline and inhaled beta 2‐adrenergic receptor agonist
Study: 8694041
Drug: Beta 2‐adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 2‐adrenergic receptor agonist and corticosteroid taper
Study: 6338693
Drug: Sucrose polyester
Normalized name: polyester-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose polyester (SPE) 8 g/day
Study: 6338693
Drug: Sucrose polyester
Normalized name: polyester-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose polyester (SPE) 16 g/day
Study: 7543597
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of the AUA symptom index